S&P 500   3,384.56 (+0.12%)
DOW   27,937.56 (-0.14%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,384.56 (+0.12%)
DOW   27,937.56 (-0.14%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,384.56 (+0.12%)
DOW   27,937.56 (-0.14%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,384.56 (+0.12%)
DOW   27,937.56 (-0.14%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
Log in

NASDAQ:NDRAENDRA Life Sciences Stock Price, Forecast & News

$0.90
-0.03 (-3.10 %)
(As of 08/13/2020 12:57 PM ET)
Add
Compare
Today's Range
$0.88
Now: $0.90
$0.92
50-Day Range
$0.89
MA: $0.96
$1.05
52-Week Range
$0.60
Now: $0.90
$2.25
Volume7,900 shs
Average Volume311,430 shs
Market Capitalization$14.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NDRA
CUSIPN/A
Phone734-335-0468

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$0.57 per share

Profitability

Net Income$-13,310,000.00

Miscellaneous

Employees11
Market Cap$14.75 million
Next Earnings Date8/14/2020 (Confirmed)
OptionableNot Optionable
$0.90
-0.03 (-3.10 %)
(As of 08/13/2020 12:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions

How has ENDRA Life Sciences' stock price been impacted by Coronavirus?

ENDRA Life Sciences' stock was trading at $1.0029 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NDRA stock has decreased by 10.1% and is now trading at $0.9012.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ENDRA Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ENDRA Life Sciences
.

When is ENDRA Life Sciences' next earnings date?

ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for ENDRA Life Sciences
.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc (NASDAQ:NDRA) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.29) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.29).
View ENDRA Life Sciences' earnings history
.

What price target have analysts set for NDRA?

1 Wall Street analysts have issued 1-year target prices for ENDRA Life Sciences' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate ENDRA Life Sciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 565.8% from the stock's current price.
View analysts' price targets for ENDRA Life Sciences
.

Has ENDRA Life Sciences been receiving favorable news coverage?

Media headlines about NDRA stock have been trending extremely negative recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ENDRA Life Sciences earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about ENDRA Life Sciences
.

Are investors shorting ENDRA Life Sciences?

ENDRA Life Sciences saw a increase in short interest in February. As of February 15th, there was short interest totaling 657,000 shares, an increase of 13.2% from the January 31st total of 580,300 shares. Based on an average daily volume of 142,000 shares, the days-to-cover ratio is presently 4.6 days.
View ENDRA Life Sciences' Short Interest
.

Who are some of ENDRA Life Sciences' key competitors?

What other stocks do shareholders of ENDRA Life Sciences own?

Who are ENDRA Life Sciences' key executives?

ENDRA Life Sciences' management team includes the following people:
  • Mr. Francois Michelon, Chairman & CEO (Age 53)
  • Mr. David R. Wells, CFO & Sec. (Age 57)
  • Mr. Michael Thornton, Chief Technology Officer (Age 51)
  • Dr. Jonathan Behr Ph.D., Co-Founder
  • Mr. Steve Freeman, HR Leader

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

What is ENDRA Life Sciences' stock symbol?

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

Who are ENDRA Life Sciences' major shareholders?

ENDRA Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include ICM Asset Management Inc. WA (2.45%) and Virtu Financial LLC (0.16%). Company insiders that own ENDRA Life Sciences stock include Anthony Digiandomenico, David R Wells, Longboard Capital Advisors, Ll, Lou Basenese, Michael Harsh and Michael Milos Thornton.
View institutional ownership trends for ENDRA Life Sciences
.

Which institutional investors are selling ENDRA Life Sciences stock?

NDRA stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA.
View insider buying and selling activity for ENDRA Life Sciences
.

Which institutional investors are buying ENDRA Life Sciences stock?

NDRA stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought ENDRA Life Sciences stock in the last two years include Anthony Digiandomenico, David R Wells, Lou Basenese, Michael Harsh, and Michael Milos Thornton.
View insider buying and selling activity for ENDRA Life Sciences
.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ENDRA Life Sciences' stock price today?

One share of NDRA stock can currently be purchased for approximately $0.90.

How big of a company is ENDRA Life Sciences?

ENDRA Life Sciences has a market capitalization of $14.75 million and generates $10,000.00 in revenue each year. The company earns $-13,310,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.

What is ENDRA Life Sciences' official website?

The official website for ENDRA Life Sciences is www.endrainc.com.

How can I contact ENDRA Life Sciences?

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.